We are pleased to invite investors and analysts to participate in our virtual event on Monday,  6 June 2022, highlighting Roche data presented during the congress scientific program from June 3 – 7 2022 and our early-stage oncology portfolio.

16:00 – 17:30 CEST / 15:00 - 16:30 BST
09:00 – 10:30 am CDT / 7:00 – 8:30 am PDT
 

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here

Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
 
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
 
A replay of the webcast will be available via > ir.roche.com
 
*privacy notice

Best regards,
 

Bruno Eschli 
Head of Investor Relations
Sabine Borngräber
Investor Relations Officer
 


 

Roche Investor Relations 
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

 
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

 
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

 
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com

 
  
Investor Relations North America 
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
 

 


get the latest news and updates to your inbox.